Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trimodality therapy with or without durvalumab for muscle-invasive bladder cancer
ISRCTN65058008Phase 2Active, not recruiting
- Sponsor
- University Hospital Southampton NHS Foundation Trust
- Start
- Aug 2020
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 2, randomised, open-label trial of durvalumab in muscle-invasive bladder cancer (MIBC) and transitional cell carcinoma of the bladder (TCC) (2 arms), sponsored by University Hospital Southampton NHS Foundation Trust. Primary endpoints: Disease-free survival, Time to death and 1 more. Started Aug 2020; status: active, not recruiting.
02
Drugs
durvalumab
03
Conditions
muscle-invasive bladder cancer (MIBC)transitional cell carcinoma of the bladder (TCC)
Beyond the preview
Go deeper on ISRCTN65058008.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN65058008.